- Home
- VRPX vs DRMA Comparison
VRPX vs DRMA Comparison
Compare VRPX & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRPX
- DRMA
- Stock Information
- Founded
- VRPX 2016
- DRMA 2014
- Country
- VRPX United States
- DRMA United States
- Employees
- VRPX N/A
- DRMA N/A
- Industry
- VRPX Medicinal Chemicals and Botanical Products
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- VRPX Health Care
- DRMA Health Care
- Exchange
- VRPX Nasdaq
- DRMA Nasdaq
- Market Cap
- VRPX 2.2M
- DRMA 1.9M
- IPO Year
- VRPX 2021
- DRMA 2021
- Fundamental
- Price
- VRPX $0.62
- DRMA $1.58
- Analyst Decision
- VRPX Hold
- DRMA Strong Buy
- Analyst Count
- VRPX 1
- DRMA 1
- Target Price
- VRPX N/A
- DRMA $6.00
- AVG Volume (30 Days)
- VRPX 355.8K
- DRMA 188.1K
- Earning Date
- VRPX 11-13-2024
- DRMA 11-07-2024
- Dividend Yield
- VRPX N/A
- DRMA N/A
- EPS Growth
- VRPX N/A
- DRMA N/A
- EPS
- VRPX N/A
- DRMA N/A
- Revenue
- VRPX N/A
- DRMA N/A
- Revenue This Year
- VRPX N/A
- DRMA N/A
- Revenue Next Year
- VRPX N/A
- DRMA N/A
- P/E Ratio
- VRPX N/A
- DRMA N/A
- Revenue Growth
- VRPX N/A
- DRMA N/A
- 52 Week Low
- VRPX $0.36
- DRMA $1.22
- 52 Week High
- VRPX $8.00
- DRMA $14.63
- Technical
- Relative Strength Index (RSI)
- VRPX 48.62
- DRMA 52.05
- Support Level
- VRPX $0.36
- DRMA $1.22
- Resistance Level
- VRPX $0.78
- DRMA $1.43
- Average True Range (ATR)
- VRPX 0.08
- DRMA 0.13
- MACD
- VRPX 0.01
- DRMA 0.02
- Stochastic Oscillator
- VRPX 62.13
- DRMA 76.60
About VRPX Virpax Pharmaceuticals Inc.
Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.